e-learning
resources
Amsterdam 2015
Monday, 28.09.2015
Bronchiectasis and NTM infections: clinical and functional characterisation
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Effectiveness of inhaled colistin by iNeb® device in non-CF bronchiectasis and chronic pseudomonas infection
Juan Manuel Lebron Ramos (Marbella, Spain), Juan Manuel Lebron Ramos, Luis Fernandez de Rota Garcia, Alicia Padilla Galo, Begoña Tortajada Goitia, Jose Joaquin Cebrian Gallardo, Francisco Rivas Ruiz
Source:
International Congress 2015 – Bronchiectasis and NTM infections: clinical and functional characterisation
Session:
Bronchiectasis and NTM infections: clinical and functional characterisation
Session type:
Thematic Poster Session
Number:
2625
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Juan Manuel Lebron Ramos (Marbella, Spain), Juan Manuel Lebron Ramos, Luis Fernandez de Rota Garcia, Alicia Padilla Galo, Begoña Tortajada Goitia, Jose Joaquin Cebrian Gallardo, Francisco Rivas Ruiz. Effectiveness of inhaled colistin by iNeb® device in non-CF bronchiectasis and chronic pseudomonas infection. Eur Respir J 2015; 46: Suppl. 59, 2625
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Observational cohort study of pulmonary exacerbations in alpha-1 antitrypsin deficiency
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Related content which might interest you:
Inhaled colistin in patients with non - cystic fibrosis bronchiectasis and chronic pseudomonas aeruginosa bronquial infection
Source: International Congress 2016 – Possible phenotypes of bronchiectasis and exacerbations
Year: 2016
Patients with no cystic fibrosis bronchiectasis colonized by
pseudomonas aeruginosa
: Role of inhaled colistin
Source: International Congress 2014 – Epidemiology, scores and outcomes of respiratory infections
Year: 2014
Inhaled colistin in elderly patients with bronchiectasis and chronic bronchial infection with pseudomonas
Source: Annual Congress 2012 - Management of severe respiratory infections
Year: 2012
Non CF bronchiectasis: The effect of inhaled antibiotics (tobramycin and colistin) in patients with pseudomonas aeruginosa
Source: International Congress 2014 – Interventions and other therapeutic approaches in respiratory infections
Year: 2014
Effect of long term azithromycin on exacerbations in non CF bronchiectasis
Source: International Congress 2014 – Antibiotics, antifungals and other therapeutic options
Year: 2014
Efficacy and safety of inhaled antibiotics for chronic pseudomonas infection in cystic fibrosis: Network meta-analysis
Source: International Congress 2016 – Cystic fibrosis: inflammation, microbiology, management and monitoring
Year: 2016
Effectiveness and adherence to treatment with nebulized colistimethate sodium (Promixin®) in non-cystic fibrosis bronchiectasis colonized by pseudomonas aeruginosa (PsA)
Source: International Congress 2015 – Bronchiectasis and NTM infections: clinical aspects and research outlook
Year: 2015
Efficacy of ciprofloxacin against resistant mucoid or non-mucoid
P. aeruginosa
isolated from non-cystic fibrosis bronchiectasis (NCFB) patients considering lung pharmacokinetics after ciprofloxacin DPI treatment
Source: International Congress 2014 – Antibiotics, antifungals and other therapeutic options
Year: 2014
Azithromycin therapy and pseudomonas aeruginosa isolation in a non-cystic fibrosis bronchiectasis cohort
Source: International Congress 2015 – Adult bronchiectasis: risk factors and future perspectives
Year: 2015
The low dose macrolides for prevention of exacerbations in non-CF bronchiectasis
Source: International Congress 2015 – Management of asthma and other respiratory diseases in primary care
Year: 2015
Prolonged oral corticosteroid therapy in allergic bronchopulmonary aspergillosis (ABPA) treatment does not increase pseudomonas aeruginosa risk
Source: International Congress 2015 – Cystic fibrosis: microbiology, immunology and assessment
Year: 2015
Role of stenotrophomonas maltophilia infection in CF pulmonary exacerbations
Source: Annual Congress 2013 –Difficult and rare respiratory infections
Year: 2013
Acute exacerbations of COPD due to pseudomonas aeruginosa: Impact of antimicrobial resistance
Source: International Congress 2015 – Infection in COPD: different aspects of the host/pathogen balance
Year: 2015
Inhaled antimicrobials
Source: ERS webinar 2020: Inhaled antimicrobials
Year: 2020
Eradication treatment in Non CF bronchiectasis: The effect of inhaled antibiotics (tobramycin and colistin) on patients with pseudomonas aeruginosa
Source: International Congress 2017 – Clinical update on bronchiectasis and nontuberculous mycobacteria (NTM) infections
Year: 2017
Nicotinamide and bacterial killing in patients with non-cystic fibrosis bronchiectasis
Source: International Congress 2014 – Antibiotics, antifungals and other therapeutic options
Year: 2014
Adherence with inhaled colistimethate sodium during a 6 month study in patients with non-cystic fibrosis bronchiectasis
Source: Annual Congress 2013 –Treating bronchiectasis in respiratory patients
Year: 2013
Inhaled antibiotics in chronic airway infections
Source: Eur Respir Monogr 2017; 75: 57-79
Year: 2017
The clinical impact of nebulised antibiotics in adults with bronchiectasis and chronic pseudomonas aeruginosa
Source: Virtual Congress 2020 – Non-tuberculous mycobacterial infections and bronchiectasis
Year: 2020
COPD and
pseudomonas aeruginosa
, an association
Source: International Congress 2014 – Resistance, bacteriological profile and comorbidities in respiratory infections
Year: 2014
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept